Misonix (NASDAQ:MSON) changed 4.45% to recent value of $25.34. The stock transacted 140211 shares during most recent day however it has an average volume of 39.8K shares. It spotted trading -4.05% off 52-week high price. On the other end, the stock has been noted 107.70% away from the low price over the last 52-weeks.
Misonix (NASDAQ:MSON) a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, announced that it has received a letter from the Division of Enforcement of the Securities and Exchange Commission (the SEC) on June 18, 2019, stating that the SEC has concluded its investigation of Misonix and that, based on the information it has as of the date of the letter, it does not intend to recommend an enforcement action by the SEC against Misonix with respect to the matters described below.
As previously disclosed, with the assistance of outside counsel, Misonix conducted a voluntary investigation into the business practices of the independent Chinese entity that previously distributed Misonix’s products in China and Misonix’s knowledge of those business practices, which may have had implications under the U.S. Foreign Corrupt Practices Act, as well as into various internal controls issues identified during the investigation. On September 27, 2016 and September 28, 2016, Misonix voluntarily contacted the SEC and the Department of Justice, respectively, to advise both agencies of these potential issues and has fully cooperated with those agencies in their subsequent inquiry and investigation relating to these matters.
Stavros Vizirgianakis, President and Chief Executive Officer of Misonix, commented,We are pleased the SEC has concluded its investigation without recommending any enforcement action. Looking ahead, we remain focused on executing on our long-range strategic growth plan with the goal of creating added shareholder value and will continue to seek to operate at the highest levels of ethics, transparency and compliance while maintaining our overarching commitment to improving patient outcomes. MSON has a gross margin of 70.50% and an operating margin of -18.10% while its profit margin remained -18.10% for the last 12 months. Its earnings per share (EPS) expected to touch remained -205.90% for this year while earning per share for the next 5-years is expected to reach at 30.00%.
The company has 9.23M of outstanding shares and 7.8M shares were floated in the market. According to the most recent quarter its current ratio was 3.7 that represents company’s ability to meet its current financial obligations. The price moved ahead of 7.30% from the mean of 20 days, 24.48% from mean of 50 days SMA and performed 37.04% from mean of 200 days price. Company’s performance for the week was 0.84%, 20.38% for month and YTD performance remained 58.28%.
Christopher Abbott joined the themostactivestocks.review, after more than 10 years of experience in writing financial and business news, most recently as Investment Editor and writer. He also has a vast knowledge of stock trading. He earned bachelor degree from Union College with a focus in Business Administration. Christopher is the Senior Editor for themostactivestocks.review and market movers section. He also holds an MBA from Penn State University He has two daughter and two children.
Address: 1140 Water Street, Concord, California
Phone Number: 925-348-4776
Email: [email protected]